{
    "clinical_study": {
        "@rank": "72065", 
        "arm_group": [
            {
                "arm_group_label": "Oncoxin", 
                "arm_group_type": "Active Comparator", 
                "description": "Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days"
            }, 
            {
                "arm_group_label": "Oncoxin & Suranix", 
                "arm_group_type": "Active Comparator", 
                "description": "Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days"
            }, 
            {
                "arm_group_label": "Supportive treatment", 
                "arm_group_type": "No Intervention", 
                "description": "Only supportive treatment. No chemotherapy, radoiotherapy, ablation or surgical intervention will be carried out."
            }
        ], 
        "brief_summary": {
            "textblock": "Oncoxin in combination with Surafenib is safe and results in improved survival in patients\n      with hepatocellular carcinoma (HCC)"
        }, 
        "brief_title": "Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Quality of Life", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "To assess therapeutic efficacy and safety of Oncoxin plus Surafenib in hepatocellular\n      carcinoma\n\n      To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma\n      patients after administration of Oncoxin plus Surafenib\n\n      To see if there is reduction tumor size and or number in hepatocellular carcinoma patients\n      after administration of Oncoxin plus Surafenib\n\n      To see if there is improvement of quality of life in hepatocellular carcinoma patients after\n      administration of Oncoxin plus Surafenib\n\n      To see if there is improved survival in hepatocellular carcinoma patients after\n      administration of Oncoxin plus Surafenib"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with HCC irrespective of etiology, age, gender and status of underlying\n             liver disease.\n\n          -  Patients with HCC who are not suitable candidates for established modalities of\n             treatment i.e. surgery and/or chemotherapy.\n\n          -  Patients with HCC who have evidence of tumor metastasis\n\n          -  Patients with HCC who are voluntarily unwilling to take established modalities of\n             treatment i.e. surgery and/or chemotherapy.\n\n          -  Patients with HCC in whom all possible treatment options have been exhausted.\n\n        Exclusion Criteria:\n\n          -  Patients with HCC who are suitable candidates for established modalities of treatment\n             i.e. surgery and/or chemotherapy.\n\n          -  Patients with HCC who have no evidence of tumor metastasis\n\n          -  Patients with HCC who are willing to take established modalities of treatment i.e.\n             surgery and/or chemotherapy.\n\n          -  Patients with HCC who are voluntarily unwilling to be included in the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01747642", 
            "org_study_id": "OP2"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Oncoxin", 
                    "Oncoxin & Suranix"
                ], 
                "description": "Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days", 
                "intervention_name": "Oncoxin", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Oncoxin & Suranix", 
                "description": "Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days", 
                "intervention_name": "Suranix", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Nexavar", 
                    "Suranib"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatocellular carcinoma", 
            "Oncoxin", 
            "Surafenib"
        ], 
        "lastchanged_date": "December 11, 2012", 
        "link": {
            "description": "Dr. Mamun A. Mahtab is the PI of this study", 
            "url": "http://www.drmahatab.org"
        }, 
        "location": {
            "contact": {
                "email": "shwapnil@agni.com", 
                "last_name": "Mamun A Mahtab, MD, FACG", 
                "phone": "+8801711567275"
            }, 
            "contact_backup": {
                "email": "crobangladesh@gmail.com", 
                "last_name": "Helal Uddin, BSc", 
                "phone": "+880-1819251514"
            }, 
            "facility": {
                "address": {
                    "city": "Dhaka", 
                    "country": "Bangladesh", 
                    "zip": "1215"
                }, 
                "name": "Farabi General Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Mamun A Mahtab, MD, FACG", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Lovely Begum, BPharm", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Bangladesh"
        }, 
        "number_of_arms": "3", 
        "official_title": "Study to Evaluate Safety and Therapeutic Efficacy of a Combination Therapy of 'Oncoxin', a Nutritional Supplement and Surafenib, a Multikinase Inhibitor in Patients With Hepatocellular Carcinoma", 
        "overall_official": {
            "affiliation": "Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh", 
            "last_name": "Mamun A Mahtab, MD, FACG", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Bangladesh: Directorate of Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To study the number of participants who have prolonged survival in months after receiving Oncoxin plus Surafenib for 24 weeks", 
            "measure": "Number of patients who have prolonged survival", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01747642"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To see whether Oncoxin plus Surafenib results in reduction in serum alpha-fetoprotein level in ng/ml and decrease in tumor size in mm in hepatocellular carcinoma patients off treatment for 24 weeks, after receiving Oncoxin plus Surafenib for 24 weeks.", 
            "measure": "Reduction in serum alpha-fetoprotein level and decrease in tumor size", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "source": "Clinical Research Organization, Dhaka, Bangladesh", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Clinical Research Organization, Dhaka, Bangladesh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}